Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 15/20 | 0.57 |
| ▸ | GABRB3 | P28472 | 15/20 | 0.57 |
| ▸ | GABRA5 | P31644 | 15/20 | 0.57 |
| ▸ | GABRA3 | P34903 | 15/20 | 0.57 |
| ▸ | GABRA1 | P14867 | 11/20 | 0.57 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.57 |
| ▸ | HTR5A | P47898 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2652467 | 0.83 | GABRG2 (0.58) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2652776 | 0.75 | GABRG2 (0.46) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2651661 | 0.73 | GABRA1 (0.51) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL1691424 | 0.73 | HTR3A (0.45) | CYP11B2HTR3AHRH3TRPA1 | |
| SCHEMBL2653096 | 0.73 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2652803 | 0.72 | GABRG2 (0.74) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2653933 | 0.72 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2652023 | 0.71 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2652699 | 0.71 | GABRA1 (0.50) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2652153 | 0.71 | PDE3B (0.44) | TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1532120-B1 | PHENYLPYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2009-01-14 | — | — | EP | disclosed |
| US-20060235021-A1 | Phenylpyridazine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2006-10-19 | — | — | US | disclosed |
| EP-1532120-A1 | PHENYLPYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004014865-A1 | PHENYLPYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235021-A1 | Phenylpyridazine derivatives as ligands for gaba receptors | GABRA5, GABRA2, GABRA3 | GABRG2 20/4885GABRB3 8/4885GABRA5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.